Academic Journal
Recommendations for the management of myasthenia gravis in Belgium
| Τίτλος: | Recommendations for the management of myasthenia gravis in Belgium |
|---|---|
| Συγγραφείς: | De Bleecker, Jan L, Remiche, Gauthier, Alonso-Jiménez, Alicia, Van Parys, Vinciane, Bissay, Véronique, DELSTANCHE, Stéphanie, Claeys, Kristl G |
| Συνεισφορές: | Janssen Pharmaceutica, UCL - SSS/IONS/NEUR - Clinical Neuroscience, UCL - (SLuc) Service de neurologie, Neuroprotection & Neuromodulation, Clinical sciences, Neurology |
| Πηγή: | Acta Neurol Belg Acta neurologica Belgica, Vol. 124, no.4, p. 1371-1383 (2024) Acta neurologica Belgica |
| Στοιχεία εκδότη: | Springer Science and Business Media LLC, 2024. |
| Έτος έκδοσης: | 2024 |
| Θεματικοί όροι: | Clinical Neurology, Guideline, Sciences de la santé humaine, DOUBLE-BLIND, 03 medical and health sciences, 0302 clinical medicine, ECULIZUMAB, Belgium, Neurologie, Myasthenia Gravis, Humans, Human health sciences, Treatment recommendations, Myasthenia gravis, Science & Technology, Neurology & Neurosurgery, Clinical management, Myasthenia Gravis/diagnosis, Neurosciences, 3202 Clinical sciences, Disease Management, 1103 Clinical Sciences, EFFICACY, INTERNATIONAL CONSENSUS GUIDANCE, 3. Good health, PREGNANCY, Neurology, SAFETY, Therapies, 3209 Neurosciences, Practice Guidelines as Topic, Human medicine, Myasthenia Gravis/therapy, Neurology (clinical), Neurosciences & Neurology, Practice Guidelines as Topic/standards, 1109 Neurosciences, Life Sciences & Biomedicine |
| Περιγραφή: | International guidelines on the treatment of myasthenia gravis (MG) have been published but are not tailored to the Belgian situation. This publication presents recommendations from a group of Belgian MG experts for the practical management of MG in Belgium. It includes recommendations for treatment of adult patients with generalized myasthenia gravis (gMG) or ocular myasthenia gravis (oMG). Depending on the MG-related antibody a treatment sequence is suggested with therapies that can be added on if the treatment goal is not achieved. Selection of treatments was based on the level of evidence of efficacy, registration and reimbursement status in Belgium, common daily practice and the personal views and experiences of the authors. The paper reflects the situation in February 2024. In addition to the treatment considerations, other relevant aspects in the management of MG are addressed, including comorbidities, drugs aggravating disease symptoms, pregnancy, and vaccination. As many new treatments might potentially come to market, a realistic future perspective on the impact of these treatments on clinical practice is given. In conclusion, these recommendations intend to be a guide for neurologists treating patients with MG in Belgium. |
| Τύπος εγγράφου: | Article Other literature type |
| Περιγραφή αρχείου: | 1 full-text file(s): application/pdf |
| Γλώσσα: | English |
| ISSN: | 2240-2993 0300-9009 |
| DOI: | 10.1007/s13760-024-02552-7 |
| Σύνδεσμος πρόσβασης: | https://pubmed.ncbi.nlm.nih.gov/38649556 https://hdl.handle.net/2078.1/293807 https://repository.uantwerpen.be/docstore/d:irua:23651 https://hdl.handle.net/10067/2060290151162165141 https://biblio.vub.ac.be/vubir/recommendations-for-the-management-of-myasthenia-gravis-in-belgium(1b91b9a5-7124-4a65-8c48-93f766dc4d92).html |
| Rights: | CC BY |
| Αριθμός Καταχώρησης: | edsair.doi.dedup.....17bc3b6e07707a0bc0b6d8a5d06128a3 |
| Βάση Δεδομένων: | OpenAIRE |
| ISSN: | 22402993 03009009 |
|---|---|
| DOI: | 10.1007/s13760-024-02552-7 |